Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of rozanolixizumab in adults with generalized myasthenia gravis
jRCT2080225254Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of rozanolixizumab in myasthenia gravis (MG) (2 arms), sponsored by UCB. Started Jul 2020; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2080225254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225254.